Paraoxon

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name

Paraoxon

Accession Number

DB13495

Description

Not Available

Type

Small Molecule

Groups

Experimental

Structure

Similar Structures

Weight: Average: 275.195
Monoisotopic: 275.055873697
Chemical Formula: C₁₀H₁₄NO₆P

Synonyms

Not Available

External IDs

E-600
E600

Pharmacology

: Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication: Not Available
Contraindications & Blackbox Warnings: Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity: Not Available
Affected organisms: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Acebutolol	Paraoxon may increase the bradycardic activities of Acebutolol.
Acetylcholine	The risk or severity of adverse effects can be increased when Paraoxon is combined with Acetylcholine.
Aclidinium	Paraoxon may increase the neuromuscular blocking activities of Aclidinium.
Amantadine	The therapeutic efficacy of Amantadine can be decreased when used in combination with Paraoxon.
Amifampridine	The risk or severity of adverse effects can be increased when Paraoxon is combined with Amifampridine.
Amitriptyline	The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Paraoxon.
Amobarbital	The therapeutic efficacy of Amobarbital can be decreased when used in combination with Paraoxon.
Amoxapine	The therapeutic efficacy of Amoxapine can be decreased when used in combination with Paraoxon.
Anisotropine methylbromide	The therapeutic efficacy of Anisotropine methylbromide can be decreased when used in combination with Paraoxon.
Aripiprazole	The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Paraoxon.

Improve patient outcomes

Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.

Learn more

Food Interactions

Not Available

Chemical Identifiers

UNII: Q9CX8P80JW
CAS number: 311-45-5
InChI Key: WYMSBXTXOHUIGT-UHFFFAOYSA-N
InChI: InChI=1S/C10H14NO6P/c1-3-15-18(14,16-4-2)17-10-7-5-9(6-8-10)11(12)13/h5-8H,3-4H2,1-2H3
IUPAC Name: diethyl 4-nitrophenyl phosphate
SMILES: CCOP(=O)(OCC)OC1=CC=C(C=C1)[N+]([O-])=O

References

General References

Not Available

External Links

Human Metabolome Database: HMDB0013035
KEGG Compound: C06606
ChemSpider: 9026
BindingDB: 50240416
ChEBI: 27827
ChEMBL: CHEMBL23838
ZINC: ZINC000001530487
Wikipedia: Paraoxon

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count

Pharmacoeconomics

Manufacturers: Not Available
Packagers: Not Available
Dosage Forms: Not Available
Prices: Not Available
Patents: Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	1.44 mg/mL	ALOGPS
logP	2.05	ALOGPS
logP	2.43	ChemAxon
logS	-2.3	ALOGPS
pKa (Strongest Basic)	-9.2	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	90.58 Å²	ChemAxon
Rotatable Bond Count	7	ChemAxon
Refractivity	64.7 m³·mol^-1	ChemAxon
Polarizability	24.97 Å³	ChemAxon
Number of Rings	1	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
GC-MS Spectrum - GC-EI-TOF	GC-MS	splash10-0a4m-4910000000-9e80686be84777f12897
Mass Spectrum (Electron Ionization)	MS	splash10-054k-9840000000-ed91d6d60187378e30e6
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Drug created on June 23, 2017 20:43 / Updated on June 12, 2020 16:53

Paraoxon

Identification

Structure for Paraoxon (DB13495)

Pharmacology

Interactions

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra